Metabolism as Platform Medicine

Executive Summary

The constraint has changed

For much of its history, metabolic medicine advanced through discovery and specialization: identifying the signals, receptors, pathways, and feedback loops that connect glucose, adiposity, appetite, liver fat, kidney function, and cardiovascular risk. Specialization gave medicine the tools to see each of these mechanisms in detail — glucose handling in diabetes, hemodynamics in heart failure, filtration in kidney disease, fibrosis in liver disease, appetite and adiposity in obesity. That work built the knowledge base the field now stands on. But the deeper each domain looked, the more clearly the same biology reappeared across them. The next step is not to abandon specialization, but to connect what specialization made visible.

No single medical specialty currently “practices metabolism” as an integrated field. Evidence is still generated through specialties, endpoints, indications, labels, and payer pathways that were built one organ at a time — a structure that was rational for the questions it was designed to answer.

It is now being asked to evaluate therapies whose effects reach across heart, kidney, liver, adipose tissue, brain, and pancreatic islet. The biology is integrated; the proof remains compartmentalized. That is the translational gap as it actually exists in 2026 — not only the bench-to-bedside gap between a mechanism and a first approval, but the gap between system-level biology and the organ-specific structures still used to prove, label, reimburse, and defend it.

We call this reading metabolism as platform medicine: a strategic lens, not a regulatory category. It treats a shared mechanism, rather than the organ it was first studied in, as the unit of strategy.

The pattern is already visible in the two leading classes. SGLT2 inhibitors grew from a diabetes therapy into foundational heart-failure and chronic-kidney-disease medicine across a decade of dedicated outcomes trials.¹² GLP-1 and incretin therapies expanded faster, gathering evidence across cardiovascular risk, kidney disease, MASH, obesity, and sleep apnea.³⁴⁵ In both, the biology crossed organs before the labels did, and each crossing was won by its own trial.

Oncology has already built the infrastructure this kind of development needs: a dedicated regulatory center and biomarker-driven master protocols.⁶ Metabolism is beginning to follow — early master protocols such as SYNERGY-OUTCOMES are now enrolling⁷ — but it remains far less mature, without the institutional depth and regulatory guidance oncology spent a decade assembling.

The strategic consequence is that the advantage is shifting from discovery to evidence architecture. Development teams now have to decide earlier which endpoints, labels, payer pathways, durability data, and cross-organ proof an asset will need, because a program designed for cross-organ benefit holds a stronger, more defensible position than one that re-proves the same biology indication by indication. Commercial activity reflects the shift: cross-organ biology is now acquired as often as it is built, and the GLP-1/incretin market alone is estimated by analysts at roughly $53–63 billion for 2025, with wide variance by method.⁸

What not to overclaim is part of the same discipline. Benefit on therapy is not automatically durable disease modification. Analyst estimates are not facts. A signal across organs is not integrated evidence until a trial is built to capture it. And platform medicine in metabolism is an interpretation we argue for, not a designation that already exists.

What follows traces this evidence in depth, examines the infrastructure gap through two case studies, maps where capital is moving, and turns each into the decisions it raises for founders, pharma and business-development teams, investors, and translational groups.

2 · Why Metabolism Is Becoming Platform Medicine

Scale, biology, and budgets are colliding

The case for treating metabolism as a platform is not that the disease burden is large. It is that scale, biology, assets, and budgets are now meeting across boundaries that were built to keep them apart.

Start with the scale of the disease. An estimated 589 million adults were living with diabetes in 2024, over 90% of it type 2.¹² Chronic kidney disease affected roughly 788 million adults globally in 2023.¹³ Cardiovascular disease caused approximately 19.2 million deaths in 2023 and remains the leading cause of death worldwide.¹⁴ An estimated 890 million adults were living with obesity in 2022.¹⁵ An estimated 1.3 billion adults may have metabolic dysfunction-associated steatotic liver disease, though that figure varies by diagnostic criteria: modeled estimates fall near 16%, while some meta-analyses run closer to 38%.¹⁶

The overlap is the real point. These are not six separate epidemics. To a large degree they are the same patients, counted in different clinics: the person with type 2 diabetes who also carries obesity, kidney decline, heart-failure risk, and liver fat. Yet that patient is studied, regulated, and reimbursed as if each condition stood alone. Scale creates the opportunity. The overlap creates the strategic complexity, because a single mechanism can now touch several of those conditions at once.

Clinical medicine has recognized this. In 2023, the American Heart Association defined cardiovascular-kidney-metabolic, or CKM, syndrome.¹⁰ The emerging cardio-renal-hepatic-metabolic (CRHM) framing extends the same logic to the liver.¹¹ These frameworks validate the biology: they describe how to stage and manage a patient whose disease crosses organs. They do not prescribe how a company should generate evidence for a cross-organ asset, how a regulator should review one, or how a payer should value benefit that lands in more than one budget. Adjacent commercial work has the same boundary: McKinsey's Metabolic Health Initiative (2025) frames the opportunity through a wellness and health-economics lens, not a drug-development one.¹⁷

There is a deeper question underneath these frameworks, and it is worth naming precisely. Nosology — the discipline that decides how diseases are defined and grouped — has long treated these conditions as a cluster: “metabolic syndrome,” and now CKM, are names for the observation that they keep company. But a cluster, or a syndrome, still counts its members as separate entities that co-occur. The reading the cross-organ evidence increasingly supports is stronger: that these are, in substantial part, one connected biology expressed in different tissues rather than several diseases that happen to coincide. The strategic argument does not require that stronger reading to be formally adopted — reclassifying disease is slow, contested, and beside the commercial point. What matters is the asymmetry it exposes. The biology is already being described as more unified than the evidence system that tests and approves drugs against it, and that gap widens as cross-organ data accumulate. Whether the field ultimately settles on syndrome, cluster, or single disease, the architecture for generating proof should track the biology, not the inherited label.

The silos are not an accident, and they will not dissolve on their own. Regulatory review is organized into divisions defined by organ and indication; reimbursement is negotiated through specialty-specific budgets; trial endpoints were standardized within specialties long before a single molecule routinely spanned all three. Each structure was rational for the questions it was created to answer. Together they now lag the biology.

3 · The Evidence-Architecture Gap

What oncology built, and metabolism has not — yet

The gap here is not biological. It is architectural, and oncology shows what closing it can look like.

Over roughly a decade, oncology organized itself around one premise: that cancers are often best understood by shared mechanism and biomarker, not only by organ of origin. The FDA established an Oncology Center of Excellence in 2017.⁶ FDA guidance on biomarker-driven master protocols lets multiple therapies and sub-studies share infrastructure, control arms, and patient-assignment logic.¹⁸ A companion-diagnostic infrastructure grew alongside, and a strategic vocabulary developed in which "platform" companies were a recognized category.

The clearest embodiment came in the tissue-agnostic approval. On May 23, 2017, the FDA cleared pembrolizumab for any unresectable or metastatic solid tumor that is microsatellite-instability-high or mismatch-repair-deficient — the agency's first approval defined by a molecular feature rather than the organ of origin.³⁵ Larotrectinib followed on November 26, 2018, for NTRK-fusion-positive solid tumors, the first tissue-agnostic targeted therapy.³⁶ In both, a mechanism was proven once, against the biology, and licensed across organ sites at once — the regulatory system certifying mechanism over location.

The analogy to oncology is useful, but it is not exact. Oncology's platform logic often rests on biomarker-defined populations, where a shared molecular alteration can guide therapy across tumor types. Metabolism's current platform logic is more often revealed through mechanism pleiotropy and cross-organ outcomes: one mechanism acting across several disease domains. That difference matters. It is why patient selection, decision-grade biomarkers, and companion-diagnostic infrastructure remain open questions in metabolic disease rather than solved infrastructure. The comparison to oncology is not a claim that metabolism should copy oncology directly. It is a way to show what mature evidence architecture can look like once a field begins to organize around mechanisms that cut across inherited categories.

Metabolism does not have to look outside itself for the pattern; it has already lived a smaller version of it. For most of its modern history, diabetes was organized around a single number. Glucose was the definition, the diagnostic threshold, and the treatment target — the metabolic counterpart to the organ of origin, the inherited surface label the field built itself around. But glucose was never the whole disease. The United Kingdom Prospective Diabetes Study showed that intensively lowering it reduced microvascular complications yet produced no significant reduction during the trial in the macrovascular events that kill most patients; the cardiovascular and mortality benefit emerged only years later, in long-term post-trial follow-up — the so-called legacy effect.³⁷³⁸ And the disease beneath the number is not one thing: type 2 diabetes spans lean and obese, insulin-deficient and insulin-resistant phenotypes, and data-driven analyses now resolve adult-onset diabetes into several distinct subgroups with different complication trajectories.³⁹ The modern cross-organ drugs closed the loop on the lesson — SGLT2 inhibitors and GLP-1 receptor agonists deliver cardiovascular and renal benefit through pathways only partly about glucose at all. Targeting the number, like classifying a tumor by its site, captured something real and missed the biology underneath. It is the same move oncology made, already run once inside metabolism's own borders.

Metabolism is beginning to develop platform infrastructure, but it still lacks the institutional depth, regulatory guidance, and scale that oncology has built.

The clearest counter-example to any claim of outright absence is SYNERGY-OUTCOMES: an early master protocol in metabolic disease, a single large trial of roughly 4,500 participants studying both retatrutide and tirzepatide in patients with MASLD at risk of major adverse liver outcomes, now enrolling.⁷ It does not contradict the thesis. It confirms the direction of it. The field is already beginning to build the architecture it lacks, which is why the strategic window is open now rather than hypothetical.

A single trial, though, is not yet a system. Metabolism is early on each pillar of mature platform architecture: there is, as yet, no disease-specific Center of Excellence, no established library of master protocols beyond early entrants, no mature companion-diagnostic infrastructure, and no settled cross-organ regulatory guidance.

The effect shows up in how indications are won. To date, each approved GLP-1 and SGLT2 indication has required its own organ-specific Phase 3 program¹⁹ — pipeline logic applied to platform-like biology. This is not a criticism of regulators. Organ-specific outcomes trials are how a system built on prospective, compartmentalized proof confirms benefit responsibly, and that bar has protected patients. Regulators were right to require dedicated evidence; the architecture was rational for the questions it was created to answer. The strategic issue is how early cross-organ evidence is now anticipated within it.

5 · Case Study: GLP-1 / Incretin Therapies

A mechanism that became a platform

If SGLT2 inhibitors are the historical parable, GLP-1 receptor agonists are the contemporary case: the clearest live example of platform-like biology, and of the evidence lag that still surrounds it.

GLP-1 receptor agonists have shown cross-organ benefit in dedicated Phase 3 trials spanning cardiovascular risk, kidney disease, MASH, and obstructive sleep apnea (see Table 1). The pattern matches SGLT2 — one mechanism proven through sequential organ-specific trials — but compressed in time and increasingly designed rather than discovered. The commercial scale that followed is real: Eli Lilly's tirzepatide alone generated $36.5 billion in fiscal 2025.²⁴

This is exactly where restraint matters, because the GLP-1 story is the easiest in medicine to overstate. Three caveats belong in any rigorous reading.

First, persistence. Real-world GLP-1 persistence has been low, with some analyses finding roughly 14% of patients still on therapy at three years in earlier cohorts, though persistence appears to be improving among more recent initiators.²⁵ Benefit on therapy and benefit over a population's lifetime are not the same thing.

Second, weight regain after discontinuation, where the evidence conflicts and should be read as unresolved. Some analyses show substantial regain toward baseline after stopping. A large company-commissioned real-world analysis of more than 135,000 records found roughly 68% of patients maintaining or continuing to lose weight at six months post-discontinuation.²⁶ The findings are not reconciled, and the honest position is to say so.

Third, body composition. Weight lost is not uniformly fat. Lean-mass preservation is moving from footnote to differentiator: in the BELIEVE phase 2 trial, combining bimagrumab with semaglutide limited lean-mass loss to about 2.9% versus about 7.4% with semaglutide alone, with roughly 92% of weight loss coming from fat in the combination group.²⁷

The implication for asset strategy is that durability, persistence, and body composition belong in the evidence plan from the start, not as later additions. A narrative that leads with peak efficacy and treats those three as footnotes understates its own risk; a credible one holds the breadth and the open questions together.

6 · Market Map

What is moving, and why it matters

Market data should support the thesis, not replace it. The figures below appear sparingly, as context for where capital is concentrating — not as forecasts, and not as valuation commentary. All market-size figures are analyst estimates that vary by scope and methodology, stated as of 2026.

The numbers matter less than the shift they describe. The cardiometabolic market is consolidating from a set of siloed franchises into one space where the same mechanism competes across several budgets at once. Three patterns stand out.

Capital is concentrating around validated cross-organ biology. Revenue sits heavily in a small number of incretin and SGLT2 assets, while the first approved MASH therapy, Madrigal's resmetirom, generated roughly $958 million in its first full year (2025) — early evidence that payers will fund metabolic-liver therapy when benefit is clear.²⁸

New modalities and geographies are entering the same space. Oral incretins reached the market in this window: oral semaglutide 25 mg was FDA-approved on December 22, 2025 and launched in January 2026,³¹ and orforglipron (Foundayo) was approved on April 1, 2026.³² China has become a significant source of metabolic drug out-licensing; mazdutide (Innovent) became the first dual GCG/GLP-1 agonist approved anywhere, cleared by China's NMPA on June 27, 2025.³³ Where a deal value is cited, it should be precise: AstraZeneca's January 2026 agreement with CSPC involved $1.2 billion upfront, up to $3.5 billion in development and regulatory milestones, and up to $13.8 billion in commercial milestones — up to roughly $18.5 billion in total if all milestones are met.³⁴

Integrated biology is now acquired as often as it is built. When large players choose to buy cross-organ mechanisms rather than develop them, much of what they are paying for is the validated, organ-spanning evidence behind the molecule, not the molecule alone.

The practical consequence is that capital is already moving toward cross-organ biology, but the value any program captures still depends on evidence quality, differentiation, durability, and access. Securing the mechanism is only part of the problem; the durable advantage sits in the evidence. None of this is a recommendation about any company or security; it maps where attention and capital are concentrating, and the direction is consistent.

8 · What Different Stakeholders Need to Decide

A diligence question for each actor

These are questions a serious team should be able to answer before it commits.

10 · How Integral BioStrategy Thinks

Our method

Our approach is deliberately narrow and explicit.

We read biology across systems rather than within a single specialty, because the mechanisms that matter in metabolic disease rarely respect organ boundaries. We organize evidence by decision relevance — what a founder, a board, a diligence team, or a development group actually needs to decide — rather than by academic completeness. And we grade every claim: proven, plausible, emerging, or unsupported. That grading is the discipline that lets a team build a position it can defend and avoid the overclaiming that quietly erodes credibility in front of regulators, partners, and investors.

Our role is to design evidence architecture. We do not run trials, negotiate payer contracts, or execute transactions.

This report is scientific and strategic analysis. It is not medical, investment, legal, tax, regulatory, or securities advice. Nothing in it guarantees regulatory approval, payer coverage, or commercial outcome, and nothing in it should be read as a recommendation regarding any company or security.